CoChat

Use of Adjectives in Abstracts when Reporting Results of Randomized, Controlled Trials from Industry and Academia

Open access

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Accurate representation of study findings is crucial to preserve public trust. The language used to describe results could affect perceptions of the efficacy or safety of interventions. We sought to compare the adjectives used in clinical trial reports of industry-authored and non-industry-authored research. METHODS: We included studies in PubMed that were randomized trials and had an abstract. Studies were classified as "non-industry-authored" when all authors had academic or governmental affiliations, or as "industry-authored" when any of the authors had industry affiliations. Abstracts were analyzed using a part-of-speech tagger to identify adjectives. To reduce the risk of false positives, the analysis was restricted to adjectives considered relevant to "coloring" (influencing interpretation) of trial results. Differences between groups were determined using exact tests, stratifying by journal. RESULTS: A total of 306,007 publications met the inclusion criteria. We were able to classify 16,789 abstracts; 9,085 were industry-authored research, and 7,704 were non-industry-authored research. We found a differential use of adjectives between industry-authored and non-industry-authored reports. Adjectives such as "well tolerated" and "meaningful" were more commonly used in the title or conclusion of the abstract by industry authors, while adjectives such as "feasible" were more commonly used by non-industry authors. CONCLUSIONS: There are differences in the adjectives used when study findings are described in industry-authored reports compared with non-industry-authored reports. Authors should avoid overusing adjectives that could be inaccurate or result in misperceptions. Editors and peer reviewers should be attentive to the use of adjectives and assess whether the usage is context appropriate.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40268-015-0085-9

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 11

Metadata

Authors
Cepeda, M. S., Berlin, J. A., Glasser, S. C., Battisti, W. P., & Schuemie, M. J.
Affiliations
  • Janssen Research & Development (United States) (US)
  • Johnson & Johnson (United States) (US)
Corresponding author
Cepeda, M. Soledad
Venue
Drugs in R&D
Published
2015-03
Volume
15
Issue
1
Pages
85-139
ISSN
  • 1174-5886 (ISSN-L)
  • 1179-6901
OpenAlex
W1979467607
Cited by
11
References
18
Citations by year
2025: 2 · 2023: 1 · 2021: 1 · 2020: 2 · 2019: 1 · 2018: 2 · 2015: 2
FWCI
1.55
Type
journal article
Language
en
Open access
Locations
  • Drugs in R&D (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
  • Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
  • Social Sciences › Library and Information Sciences › Academic Writing and Publishing
Keywords
adjectives, clinical trial abstracts, pharmaceutical industry, academic authors, part-of-speech tagging, randomized controlled trials, journal differences
MeSH terms
Abstracting and Indexing, Authorship, Humans, Terminology as Topic, Periodicals as Topic, Publishing, Randomized Controlled Trials as Topic, Trust

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Use of Adjectives in Abstracts when Reporting Results of Randomized, Controlled Trials from Industry and Academia. https://app.cochat.ai/papers/10.1007/s40268-015-0085-9
The paper
Cepeda, M. S., Berlin, J. A., Glasser, S. C., Battisti, W. P., & Schuemie, M. J. (2015). Use of Adjectives in Abstracts when Reporting Results of Randomized, Controlled Trials from Industry and Academia. Drugs in R&D. https://doi.org/10.1007/s40268-015-0085-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.